▪ Female or male patients aged > 18 years with germline BRCA1/2-mutated, HER2-negative ABC (i.e., local ABC that was not amenable to curative radiation or surgical cure or metastatic breast cancer), living or deceased at the time of data abstraction▪ Initiated > 1 cytotoxic chemotherapy (single agent or combination) for advanced disease (any line of therapy) from January 1, 2013, to April 30, 2018a▪ Use of nonchemotherapy-based treatments as first-line treatment for advanced disease was permitted. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.